Home＞REGULATORY
(Update) Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo(Sep.13.2017)
Chuikyo Drug Pricing Subcommittee |
The Central Social Insurance Medical Council, a health ministry reimbursement panel better known as Chuikyo, might discuss the creation of a new pricing scheme to work out the NHI prices of innovative medicines, such as ones likely to be launched in Japan ahead of the rest of the world ...
(LOG IN FOR FULL STORY)
-
With 253 Billion Yen Estimate Out, Chuikyo Members Prod MHLW to Vet Impact of Price Maintenance Premium
Sep.14
-
JGA President Sees Reduction in Number of Generic Drug Makers as “Inevitable”: Chuikyo
Sep.14
-
JPWA Expresses Concern Over Price Renegotiations, Calls for Guidelines to Curb Practice
Sep.14
-
Samurai Biotech Association Calls for NHI Price Increases When Sales Fall Below Forecasts: Chuikyo
Sep.14
-
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR Apr.20
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official Apr.19
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab Apr.17
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey Apr.17
-
Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
Apr.17
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
- Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
